{
  "docId": "019dd923-5ca1-7489-b636-bc879d1b6d64",
  "docSlug": "17680cec2cbd3510",
  "documentTitle": "Accelerated Access Review UK Mapping",
  "authorId": "Deloitte",
  "authorName": "Deloitte",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 78,
  "pageCount": 109,
  "prevPage": 77,
  "nextPage": 79,
  "slideType": "pain_points",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a process-like icon header to indicate the current stage of the deck.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "icon_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b636-bc879d1b6d64/78",
  "deckHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64#slide-78",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Our research highlighted two key challenges in the regulatory stage for the early access to innovative in vitro diagnostics",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-ba8c-7422-853f-42edd2b7239b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.13,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1f02cc7-bfa0-4396-95d3-78e97eff160a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.91,
        "x": 0.05,
        "y": 0.43
      },
      "kind": "list",
      "text": "Uneven requirements vs. in-house tests: Commercially developed in vitro diagnostics are required to generate evidence for CE marking. This is not a requirement for equivalent tests developed in-house by healthcare providers.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3822d7ba-296d-4a26-9761-db18af21f3fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.91,
        "x": 0.05,
        "y": 0.58
      },
      "kind": "list",
      "text": "Potential for greater regulatory burden: The European Union is currently finalising a new regulatory Directive for in vitro diagnostics. Some Industry bodies have raised concerns that this new system has the potential to significantly increase requirements.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0d02592-1315-4e20-b67a-f570817681c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.91,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Lack of early dialogue: Low uptake of available advice on protocol and trial design; Not seen as value-add for companies with deep experience; Seen as too large a time and cost investment for SMEs; Lack of engagement and uncertainty about effectiveness",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d046c519-fa0a-4886-b846-2e80ef1ef412",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.92,
        "x": 0.04,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "Our research highlighted two key challenges in the regulatory stage for the early access to innovative in vitro diagnostics",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12f0ef33-804d-4fb9-811e-a8b0f470985c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: Stakeholder interviews, workshops and Deloitte analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26d84f8c-caa9-4f6d-80b2-adeee6eb7a75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.33,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Key Challenges",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b94c70b9-a432-4f67-9f1d-a755b81b51b2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "2af1679f-8fac-4ab9-a03e-eb722023c64d",
      "evidence": "list/bullet: Potential for greater regulatory burden: The European Union is currently finalising a new regulatory Directive for in vitro diagnostics. Some Industry bodies have raised concerns that this new system has the",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 109,
      "from": 21,
      "beatId": "4bae8ed9-97e4-4ca8-988f-171e64b0598d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document proposes solutions to address the challenges, including streamlining development pathways and improving regulation.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 109,
      "from": 21,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "575c67ea-abbb-4bd3-80bc-943f97973ed4",
      "evidence": "The document proposes solutions to address the challenges, including streamlining development pathways and improving regulation.",
      "position": 1,
      "objective": "How can the NHS improve access to medical innovations?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.7,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}